Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
2 hedge funds and large institutions have $2.97K invested in Sonnet BioTherapeutics in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 8 closing their positions.
2.35% less ownership
Funds ownership: 2.36% → 0.01% (-2.3%)
80% less funds holding
Funds holding: 10 → 2 (-8)
99% less capital invested
Capital invested by funds: $550K → $2.97K (-$547K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 8
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$255K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$223K |
| 3 |
VF
Virtu Financial
New York
|
-$31K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$15.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $2.53K | -$3.41K | -518 | -58% |
|
2
BlackRock
New York
| $435 | – | – | – |
|
|
PWMG
3
Private Wealth Management Group
Princeton,
New Jersey
| $3 | – | – | – |
|
|
AC
4
Armistice Capital
New York
| – | -$255K | -34,000 | Closed |
|
|
SM
5
Sabby Management
Miami Beach,
Florida
| – | -$223K | -29,799 | Closed |
|
|
VF
6
Virtu Financial
New York
| – | -$31K | -4,086 | Closed |
|
|
7
Geode Capital Management
Boston,
Massachusetts
| – | -$15.7K | -2,088 | Closed |
|
|
8
Vanguard Group
Malvern,
Pennsylvania
| – | -$13.8K | -1,841 | Closed |
|
9
UBS Group
Zurich,
Switzerland
| – | -$3.75K | -500 | Closed |
|
10
Bank of America
Charlotte,
North Carolina
| – | -$27 | -4 | Closed |
|
11
Morgan Stanley
New York
| – | -$4 | -1 | Closed |
|
SONN Hedge Fund Activity: Q3 2024 in Review
2 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q3 2024, worth a combined $2.97K — down 99% from $550K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SONN and 0 opened new positions — a net loss of 8 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Armistice Capital, exiting entirely with an estimated $255K sold.
- 2 institutional investors held Sonnet BioTherapeutics (SONN) as of Q3 2024, down from 10 in Q2 2024.
- Funds reported $2.97K of Sonnet BioTherapeutics stock for Q3 2024, down 99% quarter-over-quarter.
- 0 funds opened new Sonnet BioTherapeutics positions in Q3 2024 and 8 closed out, a net change of -8 holders.
- The largest Sonnet BioTherapeutics seller in Q3 2024 was Armistice Capital, an estimated $255K sold.
Based on aggregated 13F filings for Q3 2024.